SUMMARY In a total of 71 subjects (19 controls, 24 patients with non-pancreatic gastrointestinal disease, and 27 patients with pancreatic disease) an oral pancreatic function test using N-benzoyl-L-tyrosyl-PABA (BT-PABA) was performed with simultaneous determination of the serum para-aminobenzoic acid (PABA). Urinary excretion of PABA was significantly less (p<OOOl) in patients with chronic pancreatitis (n= 12) and pancreatic carcinoma (n= 10) than in controls and in patients with non-pancreatic disease. The serum concentration curve in patients with chronic pancreatitis was significantly flattened (p<0001) compared with that of the control group and the patients with non-pancreatic gastrointestinal disease. The discrimination between the controls and the patients with chronic pancreatitis was best at 120 minutes after administration of BT-PABA (lower limit of normal: 28 ,ug/ml). The results of our study show that determination of PABA serum concentration two hours after administration of BT-PABA is as valuable an index of pancreatic function as the urinary excretion of PABA.
The oral pancreatic function test using N-benzoyl-Ltyrosyl-para-aminobenzoic acid (BT-PABA) has proved to be a simple and reliable test in detecting moderate to severe exocrine pancreatic insufficiency. In over 900 patients and controls tested we found a sensitivity of 85% for chronic pancreatitis and a specificity of 90%, which correlates well with the data from other European studies.1-5 In our experience, however, the value of the test depends to a large extent on a correctly conducted urinary collection. In some patients, particularly in elderly, severe debilitated patients, those with urological disorders, and in children, an inaccurate collection of urine will invalidate the results of the test.
It has recently become possible to measure the PABA in the serum after administration of BT-PABA. The serum concentration profile of PABA in patients with exocrine pancreatic insufficiency was shown to be significantly lower than that found in healthy controls.i8 The data are, however, too few to allow any conclusion on the value of the procedure; and furthermore, methodology of pancreatic function test used in the studies varied from one group of investigators to another. Determination of PABA in the serum instead of urine could represent an alternative pancreatic function test procedure in patients in whom urinary collection is expected to be unreliable. It was the aim of this study to examine the value of the serum determination of PABA in comparison with the urinary PABA excretion in healthy controls, in patients with extra-abdominal pathology, and with non-pancreatic, gastrointestinal diseases as well as in patients with pancreatic diseases, especially exocrine pancreatic insufficiency.
Methods

PATIENTS
Oral pancreatic function tests with determination of PABA in the urine and serum were carried out in a total of 71 patients and controls between 1981 and 1982.
CONTROLS
The control group consisted of 10 healthy volunteers (seven men and three women), aged 24 to 29 years, and nine patients of the outpatient department (six men and nine women), aged 19 to 65 years, with extra-abdominal disease, but without organic disease of the gastrointestinal tract. Patients with evidence of renal disease were excluded. BT-PABA (PFT Roche) was given in the form of three tablets each containing 333 mg of the peptide together with a breakfast consisting of one roll, 10 g of butter, jam, and 200 ml of tea. During the first hour, the patients were encouraged to drink an additional 400 ml of water or tea to ensure sufficient diuresis, and after four to five hours a lunch was allowed. The urine was collected in a single specimen over six hours, during which time blood samples of 10 ml were taken every hour. The blood was centrifuged and the serum frozen at -20°C. Before administration of BT-PABA, control urine was collected for one hour and a fasting blood sample was also taken (control value).
DETERMINATION OF PABA IN URINE AND SERUM
The PABA in the urine was determined according to the Bratton-Marshall method following hydrolysis with 30% hydrochloric acid for one hour at 100°C. lO The results were expressed as the amount of PABA excreted in the urine during six hours as percentage of the administered dose -that is, of 340 rng PABA. According to previous studies, 50% urinary PABA excretion within six hours was taken as lower limit of normal.9
The determination of PABA in the serum was preceded by deproteinisation of the serum samples: 1 ml serum was mixed with 2 ml 10% trichloroacetic acid and centrifuged at 40(0) rpm for 10 minutes. The supernatant was collected in a 5 ml Erlenmaier dish. The sediment was resuspended in 1 ml 10%4 trichloroacetic acid and subsequently centrifuged. This procedure was performed twice. The supernatant was then added to the contents of the Erlenmaier dish. Finally, 10%)7 trichloroacetic acid was added to the supernatant up to a total of 5 ml. After deproteinisation, 2 ml of the supernatant were incubated with 0(2 ml 30c% hydrochloric acid for one hour at 100°C. Subsequent to the hydrolysis the concentration of para-aminobenzoic acid was determined photometrically by the Bratton- Marshall method at 546 nm wavelength. The measurement of the extinction was taken against the control serum sample treated the same way and multiplied with a correction factor (2.6666) to obtain the extinction per millilitre of serum. By means of a standard calibration curve, the concentration of para-aminobenzoic acid in the serum was expressed in ,ug/ml. Intra-assay variation was 1 6% (n=6) and interassay variation 7 4% (n=4). STATISTICAL 
ANALYSIS
Results are expressed as mean ± standard deviation. Student's t test for paired and unpaired data was used to test for differences of the means. Regression analysis was performed according to Remington and Patients with non-pancreatic gastrointestinal disease The serum concentration curve of PABA followed the pattern of that of the controls closely, there being no significant difference between the two (Fig. 1) . In this group of 24 patients, one patient with irritable colon had an abnormal serum value of 2-1 ,ug/ml but had a normal urinary PABA excretion (60 6%) (Fig. 2 ). Four patients with normal PABA serum concentration showed urinary PABA excretion below the normal range. One of these patients suffered from an anastomotic ulcer after Billroth II gastric resection and also had prostatic hypertrophy with retention of urine, the other three had posthepatic cirrhosis, Billroth I gastric resection, and total gastric resection respectively.
Patients with pancreatic disease
In the five patients who had an acute pancreatitis, their mean serum PABA values were slighly lower than those of the controls, but the differences were not statistically significant (Table 2) . In contrast with patients with acute pancreatitis and with controls, the serum concentration curve of the patients with chronic pancreatitis was considerably flattened with a delayed, low peak concentration (2.4±0.9 ,ug/ml) occurring at 300 minutes. The PABA concentrations at 60, 120, 180, and 240 minutes were significantly lower than the corresponding values of the control group (p<0.01-0.001; Fig. 1) . In all 12 patients with chronic pancreatitis, the serum PABA concentration was abnormally low at 120 minutes (Fig. 2) .
In the 10 patients with pancreatic carcinoma, the rate of increase in serum PABA concentrations was also significantly lower than that of the controls, and a peak concentration (4-8±2-3 Ag/ml) was reached at 300 minutes (Fig. 1) incorrect either because of lack of cooperation or inability of the patient to collect the urine correctly.
As expected, the mean urinary PABA excretion was significantly less in patients with chronic pancreatitis and pancreatic carcinoma compared with the controls and with patients with nonpancreatic gastrointestinal diseases. Similarly, the serum PABA profile was flattened in chronic pancreatitis. In patients with pancreatic carcinoma, the slope of the curve was also significantly lower, the same peak concentration was reached as in the control group, but was delayed until 300 minutes. 
